<?xml version='1.0' encoding='utf-8'?>
<document id="26608671"><sentence text="Evaluation of drug-drug interaction between henagliflozin, a novel sodium-glucose co-transporter 2 inhibitor, and metformin in healthy Chinese males."><entity charOffset="44-57" id="DDI-PubMed.26608671.s1.e0" text="henagliflozin" /><entity charOffset="114-123" id="DDI-PubMed.26608671.s1.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.26608671.s1.e0" e2="DDI-PubMed.26608671.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26608671.s1.e0" e2="DDI-PubMed.26608671.s1.e1" /></sentence><sentence text="1" /><sentence text=" Henagliflozin is a novel sodium-glucose transporter 2 inhibitor and presents a complementary therapy to metformin for patients with T2DM due to its insulin-independent mechanism of action"><entity charOffset="1-14" id="DDI-PubMed.26608671.s3.e0" text="Henagliflozin" /><entity charOffset="26-40" id="DDI-PubMed.26608671.s3.e1" text="sodium-glucose" /><entity charOffset="105-114" id="DDI-PubMed.26608671.s3.e2" text="metformin" /><pair ddi="false" e1="DDI-PubMed.26608671.s3.e0" e2="DDI-PubMed.26608671.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26608671.s3.e0" e2="DDI-PubMed.26608671.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26608671.s3.e0" e2="DDI-PubMed.26608671.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26608671.s3.e1" e2="DDI-PubMed.26608671.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26608671.s3.e1" e2="DDI-PubMed.26608671.s3.e2" /></sentence><sentence text=" This study evaluated the potential pharmacokinetic drug-drug interaction between henagliflozin and metformin in healthy Chinese male subjects"><entity charOffset="82-95" id="DDI-PubMed.26608671.s4.e0" text="henagliflozin" /><entity charOffset="100-109" id="DDI-PubMed.26608671.s4.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.26608671.s4.e0" e2="DDI-PubMed.26608671.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26608671.s4.e0" e2="DDI-PubMed.26608671.s4.e1" /></sentence><sentence text=" 2" /><sentence text=" In open-label, single-center, single-arm, two-period, three-treatment self-control study, 12 subjects received 25 mg henagliflozin, 1000 mg metformin or the combination"><entity charOffset="118-131" id="DDI-PubMed.26608671.s6.e0" text="henagliflozin" /><entity charOffset="141-150" id="DDI-PubMed.26608671.s6.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.26608671.s6.e0" e2="DDI-PubMed.26608671.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26608671.s6.e0" e2="DDI-PubMed.26608671.s6.e1" /></sentence><sentence text=" Lack of PK interaction was defined as the ratio of geometric means and 90% confidence interval (CI) for combination: monotherapy being within the range of 0" /><sentence text="80-1" /><sentence text="25" /><sentence text=" 3" /><sentence text=" Co-administration of henagliflozin with metformin had no effect on henagliflozin area under the plasma concentration-time curve (AUC0-24) (GRM: 1"><entity charOffset="22-35" id="DDI-PubMed.26608671.s11.e0" text="henagliflozin" /><entity charOffset="41-50" id="DDI-PubMed.26608671.s11.e1" text="metformin" /><entity charOffset="68-81" id="DDI-PubMed.26608671.s11.e2" text="henagliflozin" /><pair ddi="false" e1="DDI-PubMed.26608671.s11.e0" e2="DDI-PubMed.26608671.s11.e0" /><pair ddi="false" e1="DDI-PubMed.26608671.s11.e0" e2="DDI-PubMed.26608671.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26608671.s11.e0" e2="DDI-PubMed.26608671.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26608671.s11.e1" e2="DDI-PubMed.26608671.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26608671.s11.e1" e2="DDI-PubMed.26608671.s11.e2" /></sentence><sentence text="08; CI: 1" /><sentence text="05, 1" /><sentence text="10) and peak plasma concentration (Cmax) (GRM: 0" /><sentence text="99; CI: 0" /><sentence text="92, 1" /><sentence text="07)" /><sentence text=" Reciprocally, co-administration of metformin with henagliflozin had no clinically significant on metformin AUC0-24 (GRM: 1"><entity charOffset="36-45" id="DDI-PubMed.26608671.s18.e0" text="metformin" /><entity charOffset="51-64" id="DDI-PubMed.26608671.s18.e1" text="henagliflozin" /><entity charOffset="98-115" id="DDI-PubMed.26608671.s18.e2" text="metformin AUC0-24" /><pair ddi="false" e1="DDI-PubMed.26608671.s18.e0" e2="DDI-PubMed.26608671.s18.e0" /><pair ddi="false" e1="DDI-PubMed.26608671.s18.e0" e2="DDI-PubMed.26608671.s18.e1" /><pair ddi="false" e1="DDI-PubMed.26608671.s18.e0" e2="DDI-PubMed.26608671.s18.e2" /><pair ddi="false" e1="DDI-PubMed.26608671.s18.e1" e2="DDI-PubMed.26608671.s18.e1" /><pair ddi="false" e1="DDI-PubMed.26608671.s18.e1" e2="DDI-PubMed.26608671.s18.e2" /></sentence><sentence text="09, CI: 1" /><sentence text="02, 1" /><sentence text="16) although there was an 11% increase in metformin Cmax (GRM 1"><entity charOffset="42-51" id="DDI-PubMed.26608671.s21.e0" text="metformin" /></sentence><sentence text="12; CI 1" /><sentence text="02, 1" /><sentence text="23)" /><sentence text=" All monotherapies and combination therapy were well tolerated" /><sentence text=" 4" /><sentence text=" Henagliflozin can be co-administered with metformin without dose adjustment of either drug"><entity charOffset="1-14" id="DDI-PubMed.26608671.s27.e0" text="Henagliflozin" /><entity charOffset="43-52" id="DDI-PubMed.26608671.s27.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.26608671.s27.e0" e2="DDI-PubMed.26608671.s27.e0" /><pair ddi="false" e1="DDI-PubMed.26608671.s27.e0" e2="DDI-PubMed.26608671.s27.e1" /></sentence><sentence text=" " /></document>